Can I read Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients on EtoBox?

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients by Spyridoula Vasileiou; LaQuisa Hill; Manik Kuvalekar; Aster G. Workineh; Ayumi Watanabe; Yovana Velazquez; Suhasini Lulla; Kimberly Mooney; Natalia Lapteva; Bambi J. Grilley; Helen E. Heslop; Cliona M. Rooney; Malcolm K. Brenner; Todd N. Eagar; George Carrum; Kevin A. Grimes; Ann M. Leen; Premal Lulla is a Medicine article available to read on EtoBox.

What is Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients about?

Defects in T-cell immunity to SARS-CoV-2 have been linked to an increased risk of severe COVID-19 (even after vaccination), persistent viral shedding and the emergence of more virulent viral variants. To address this T-cell deficit, we sought to prepare and cryopreserve banks of virus-specific T cells, which would be available as a partially HLA-matched, off-the-shelf product for immediate therapeutic use. By interrogating the peripheral blood of healthy convalescent donors, we identified immunodominant and protective T-cell target antigens, and generated and characterized polyclonal virus-specific T-cell lines with activity against multiple clinically important SARS-CoV-2 variants (including ‘delta’ and ‘omicron’). The feasibility of making and safely utilizing such virus-specific T cells clinically was assessed by administering partially HLA-matched, third-party, cryopreserved SARS-CoV-2-specific T cells (ALVR109) in combination with other antiviral agents to four individuals who were hospitalized with COVID-19. This study establishes the feasibility of preparing and delivering off-the-shelf, SARS-CoV-2-directed, virus-specific T cells to patients with COVID-19 and supports the c

Who reads Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients?

Author

Spyridoula Vasileiou; LaQuisa Hill; Manik Kuvalekar; Aster G. Workineh; Ayumi Watanabe; Yovana Velazquez; Suhasini Lulla; Kimberly Mooney; Natalia Lapteva; Bambi J. Grilley; Helen E. Heslop; Cliona M. Rooney; Malcolm K. Brenner; Todd N. Eagar; George Carrum; Kevin A. Grimes; Ann M. Leen; Premal Lulla

Publisher

Ferrata Storti Foundation (Haematologica)

Published

2022

Language

EN

Field

Medicine (Health Sciences)